Suzetrigine (a NaV1.8 inhibitor) versus placebo for acute postoperative pain: A systematic review and meta-analysis of randomized controlled trials. | Synapse
March 8, 2026
Suzetrigine (a NaV1.8 inhibitor) versus placebo for acute postoperative pain: A systematic review and meta-analysis of randomized controlled trials.
Key Points
This review aims to evaluate the efficacy of suzetrigine compared to placebo for managing acute postoperative pain.
Performed a systematic review of randomized controlled trials
Compared outcomes of suzetrigine and placebo groups
Analyzed pain levels at 24 to 48 hours post-surgery
Suzetrigine resulted in modest reductions in pain compared to placebo
Opioid consumption data were inconsistently reported, limiting conclusions on opioid-sparing effects
Abstract
Suzetrigine produced modest reductions in pain at 24 to 48 hours versus placebo. Because opioid consumption was not consistently reported, no conclusions can be drawn regarding opioid-sparing.
Like
Bookmark
Share
Cite This Study
Álvarez-Aguilar et al. (Fri,) studied this question.